Genetic medicines represent a paradigm shift in treating hereditary and acquired diseases by targeting the molecular root cause — faulty genes — rather than managing symptoms, making them one of the most consequential frontiers in modern biotechnology.
Genetic medicines work by correcting, replacing, silencing, or compensating for defective genes responsible for disease. Unlike conventional drugs that modulate biochemical pathways, these therapies intervene at the genomic level, offering the possibility of durable or even permanent therapeutic effect. Conditions such as sickle cell disease, certain inherited blindness disorders, and some cancers have seen clinical-stage gene therapy applications.
Effective delivery of genetic material into target cells is the central engineering challenge. Engineered viral vectors — particularly adeno-associated viruses — are widely used because of their natural ability to enter cells and deliver nucleic acid payloads. Lipid nanoparticles, brought to global attention through mRNA-based vaccines, offer a non-viral alternative that is scalable and less immunogenic, making them increasingly preferred for RNA-based therapies.
A critical distinction is that genetic medicines do not alter the entire DNA sequence; they target specific genes or sequences with high precision. Technologies such as CRISPR-Cas9 enable site-specific edits, while RNA interference silences particular gene expressions without modifying the broader genome. Altering the entire DNA sequence would be biologically catastrophic and is not the objective of any approved therapeutic approach.
Regulatory frameworks globally, including India's guidelines under the Central Drugs Standard Control Organisation, are evolving to address safety, germline editing concerns, equitable access, and long-term monitoring. The distinction between somatic gene therapy (affecting only the patient) and germline editing (heritable changes) raises profound ethical questions that demand robust policy oversight.
Genetic medicines hold transformative potential for diseases previously considered untreatable, but realising that potential requires proportionate regulation, investment in domestic biomanufacturing capacity, and ethical frameworks that balance innovation with societal safeguards.
GS Answer Coach grades your Mains answer on structure, substance, and conclusion — in under a minute.
Essay Coach · GS Answer Coach · Cutoff Planner · 500+ Mains PYQs — free to sign up.